Ser256
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser256  -  FOXO1A (human)

Site Information
sPrRrAAsMDNNskF   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448075
Available spectra:  2 CST

In vivo Characterization
Methods used to characterize site in vivo:
electrophoretic mobility shift ( 60 ) , immunoprecipitation ( 19 , 24 , 37 , 38 , 39 , 43 , 50 ) , mass spectrometry ( 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 16 , 17 , 18 , 20 , 21 , 22 , 23 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 36 , 40 , 41 , 42 , 48 ) , mutation of modification site ( 6 , 35 , 43 , 56 , 61 , 66 , 68 , 71 , 74 , 76 ) , phospho-antibody ( 1 , 4 , 5 , 6 , 19 , 24 , 35 , 37 , 38 , 39 , 44 , 46 , 47 , 49 , 50 , 53 , 54 , 55 , 57 , 58 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 72 , 74 , 75 , 77 ) , western blotting ( 1 , 3 , 4 , 5 , 6 , 19 , 24 , 35 , 37 , 38 , 39 , 44 , 46 , 49 , 50 , 53 , 54 , 55 , 57 , 63 , 65 , 68 , 70 , 74 , 75 , 77 )
Disease tissue studied:
bone cancer ( 46 , 58 ) , Ewing's sarcoma ( 6 ) , osteosarcoma ( 58 ) , brain cancer ( 46 ) , glioblastoma ( 46 ) , glioma ( 46 ) , breast cancer ( 39 , 46 , 63 , 75 ) , chondrosarcoma ( 58 ) , liposarcoma ( 58 ) , gastric cancer ( 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 ) , gastric carcinoma ( 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 ) , leukemia ( 5 ) , acute lymphocytic leukemia ( 5 ) , chronic myelogenous leukemia ( 5 ) , liver cancer ( 3 , 24 , 38 , 76 ) , hepatocellular carcinoma ( 38 ) , lung cancer ( 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 16 , 46 , 47 ) , non-small cell lung cancer ( 9 , 10 , 11 , 13 , 14 , 16 , 17 , 18 , 47 ) , non-small cell lung adenocarcinoma ( 9 , 10 , 11 , 12 , 13 , 14 , 16 , 17 ) , non-small cell large cell lung carcinoma ( 10 , 13 ) , non-small cell squamous cell lung carcinoma ( 12 , 18 ) , small-cell lung cancer ( 7 , 8 ) , malignant fibrous histiocytoma ( 58 ) , neuroblastoma ( 50 ) , pancreatic cancer ( 19 , 35 , 39 , 65 ) , pancreatic carcinoma ( 19 , 35 , 39 , 65 ) , soft tissue cancer ( 6 ) , leiomyosarcoma ( 58 ) , rhabdomyosarcoma ( 58 ) , hepatitis ( 53 )
Relevant cell line - cell type - tissue:
'B lymphocyte, precursor' [RAG2 (mouse), homozygous knockout] ( 5 ) , 'neuron, cortical'-brain ( 61 ) , 'neuron, hippocampal'-brain ( 61 ) , 'stem, embryonic' ( 72 ) , 21T (breast cell) ( 39 ) , 293 (epithelial) ( 19 , 23 , 37 , 46 , 48 , 49 , 56 , 68 , 71 , 72 , 74 , 77 ) , 3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout] ( 66 ) , 786-O (renal) ( 66 ) , A549 (pulmonary) ( 9 , 46 ) , A673 (muscle cell) ( 6 ) , adipocyte ( 56 ) , adipocyte-adipose tissue ( 4 ) , Aspc1 (pancreatic) ( 35 ) , BV-173 (myeloid) ( 5 ) , Cal-12T (pulmonary) ( 16 ) , Calu-3 (pulmonary) ( 11 ) , COS (fibroblast) ( 43 , 66 ) , DMS153 (pulmonary) ( 14 ) , DMS53 (pulmonary) ( 8 ) , DMS79 (pulmonary) ( 7 ) , endothelial-aorta ( 20 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 21 ) , Flp-In T-Rex-293 (epithelial) ( 21 ) , HaCaT (keratinocyte) ( 69 ) , HAEC (endothelial) ( 57 ) , HCC15 (pulmonary) ( 12 ) , HCC44 (pulmonary) ( 16 ) , HCC78 (pulmonary) ( 13 ) , HCC827 (pulmonary) ( 11 ) , HEK293T (epithelial) ( 39 , 60 ) , HeLa (cervical) ( 44 ) , Hepa 1-6 (epithelial) ( 24 ) , hepatocyte-liver ( 24 ) , HepG2 (hepatic) ( 3 , 24 , 66 , 76 ) , HUES-9 ('stem, embryonic') ( 34 ) , Huh7 (hepatic) ( 38 ) , HUVEC (endothelial) ( 49 ) , Jurkat (T lymphocyte) ( 36 , 40 , 41 , 42 , 62 , 66 , 67 ) , keratinocyte ( 1 ) , LAN-1 (neural crest) ( 50 ) , liver ( 53 ) , LNCaP (prostate cell) ( 66 ) , LOU-NH91 (squamous) ( 12 ) , lung ( 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 16 ) , MCF-7 (breast cell) [CYP19A1 (human)] ( 63 ) , MCF-7 (breast cell) ( 46 ) , MDA-MB-231 (breast cell) ( 75 ) , mesangial ( 55 ) , MKN-45 (gastric) ( 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 ) , NCI-H128 (pulmonary) ( 7 ) , NCI-H1299 (pulmonary) ( 10 ) , NCI-H1355 (pulmonary) ( 9 ) , NCI-H1417 (pulmonary) ( 7 ) , NCI-H1437 (pulmonary) ( 14 , 16 ) , NCI-H1650 (pulmonary) ( 11 ) , NCI-H1666 (pulmonary) ( 16 ) , NCI-H1703 (squamous) ( 12 , 18 ) , NCI-H1734 (pulmonary) ( 10 ) , NCI-H1781 (pulmonary) ( 13 ) , NCI-H1792 (pulmonary) ( 9 ) , NCI-H1944 (pulmonary) ( 10 ) , NCI-H1975 (pulmonary) ( 11 ) , NCI-H2073 (pulmonary) ( 12 , 14 ) , NCI-H209 (pulmonary) ( 7 , 14 ) , NCI-H2106 (pulmonary) ( 11 ) , NCI-H2228 (pulmonary) ( 13 , 17 ) , NCI-H23 (pulmonary) ( 9 ) , NCI-H2342 (pulmonary) ( 12 ) , NCI-H2405 (pulmonary) ( 16 ) , NCI-H3122 (pulmonary) ( 13 ) , NCI-H358 (pulmonary) ( 10 ) , NCI-H441 (pulmonary) ( 9 ) , NCI-H446 (pulmonary) ( 8 ) , NCI-H460 (pulmonary) ( 10 , 47 ) , NCI-H524 (pulmonary) ( 7 ) , NCI-H526 (pulmonary) ( 8 ) , NCI-H661 (pulmonary) ( 13 ) , NCI-H69 (pulmonary) ( 8 ) , NCI-H82 (pulmonary) ( 8 ) , NCI-H838 (pulmonary) ( 14 ) , PANC-1 (pancreatic) ( 35 , 39 ) , pancreas ( 65 ) , PC-12 (chromaffin) ( 61 ) , RWP1 (pancreatic) ( 19 ) , SH-SY5Y (neural crest) ( 64 ) , SK-N-MC (neural crest) ( 6 ) , SUP-B15 (B lymphocyte) ( 5 ) , T lymphocyte-blood ( 54 , 70 ) , U2OS (bone cell) ( 46 ) , U87MG (glial) ( 46 )

Upstream Regulation
Regulatory protein:
Akt1 (human) ( 57 , 77 ) , EWS (human) ( 6 ) , IL2RA (human) ( 54 ) , Notch 1 (human) ( 59 ) , p53 (human) ( 59 ) , PDK1 (human) ( 77 ) , PHLPP (human) ( 39 ) , PHLPP2 (human) ( 39 ) , PTPRJ (human) ( 49 ) , SHC1 (human) ( 64 ) , SHIP (human) ( 67 ) , Snail1 (human) ( 19 )
Putative in vivo kinases:
Akt1 (human) ( 38 , 66 , 77 )
Kinases, in vitro:
Akt1 (human) ( 60 , 73 , 74 , 77 )
Treatments:
2-deoxyglucose ( 47 ) , A-443654 ( 38 ) , AG1478 ( 75 ) , Akt-I-1 ( 44 ) , Akt-I-1,2 ( 37 ) , angiotensin-(1-7) ( 20 ) , anti-CD3 ( 70 ) , anti-CD3/CD28 ( 54 ) , AZD8055 ( 46 ) , bacterial infection ( 1 ) , BDNF ( 61 ) , beta-amyloid_40 ( 64 ) , BMS-345541 ( 5 ) , C5b-9 ( 57 ) , CTGF ( 55 ) , cycloheximide ( 37 ) , ebselen ( 64 ) , EGF ( 75 ) , estrogen_deprivation ( 63 ) , glucagon ( 3 ) , GSK690693 ( 5 ) , H2O2 ( 37 ) , hepatitis C virus expression ( 38 ) , HGF ( 24 ) , IGF-1 ( 61 , 72 , 74 , 77 ) , imatinib ( 5 ) , insulin ( 3 , 4 , 37 , 38 , 56 ) , interleukin-6-hydroxymethyl-chiro-inositol-2(R)-2-methyl-3-O-octadecylcarbonate ( 55 ) , IQA ( 62 ) , K252a ( 61 ) , LY294002 ( 44 , 55 , 61 , 62 , 75 ) , neurotrophin-3 ( 61 ) , neurotrophin-4 ( 61 ) , NGF ( 61 ) , oxidative_stress ( 51 ) , PD184352 ( 4 ) , PD98059 ( 61 , 77 ) , PP2 ( 49 ) , QLT0254 ( 65 ) , rapamycin ( 77 ) , resveratrol ( 35 , 37 ) , sardomozide ( 50 ) , SH-5 ( 57 ) , siRNA ( 49 , 57 ) , TBB ( 62 ) , UCN-01 ( 38 ) , wortmannin ( 72 , 77 )

Downstream Regulation
Effects of modification on FOXO1A:
activity, inhibited ( 60 , 76 ) , intracellular localization ( 24 , 35 , 37 , 38 , 56 , 61 , 71 , 74 ) , molecular association, regulation ( 24 , 37 , 38 , 66 , 68 , 71 ) , phosphorylation ( 74 ) , protein degradation ( 66 )
Effects of modification on biological processes:
carcinogenesis, inhibited ( 35 ) , cell growth, induced ( 6 ) , transcription, altered ( 43 , 60 ) , transcription, inhibited ( 6 , 24 , 35 , 38 , 56 , 71 , 74 , 76 )
Induce interaction with:
14-3-3 beta (human) ( 37 , 38 , 68 ) , SKP2 (human) ( 66 )
Inhibit interaction with:
DNA ( 24 , 71 )

Disease / Diagnostics Relevance
Relevant diseases:
hepatitis ( 53 )

References 

1

Ohshima J, et al. (2019) programs epithelial cells to resist ZEB2 induction by . Proc Natl Acad Sci U S A 116, 8544-8553
30971493   Curated Info

2

Shin S, et al. (2019) ERK2 regulates epithelial-to-mesenchymal plasticity through DOCK10-dependent Rac1/FoxO1 activation. Proc Natl Acad Sci U S A 116, 2967-2976
30728292   Curated Info

3

Wu Y, et al. (2018) Novel Mechanism of Foxo1 Phosphorylation in Glucagon Signaling in Control of Glucose Homeostasis. Diabetes
30201683   Curated Info

4

Rajan MR, et al. (2016) Systems-wide Experimental and Modeling Analysis of Insulin Signaling through Forkhead Box Protein O1 (FOXO1) in Human Adipocytes, Normally and in Type 2 Diabetes. J Biol Chem 291, 15806-15819
27226562   Curated Info

5

Ochodnicka-Mackovicova K, et al. (2015) NF-κB and AKT signaling prevent DNA damage in transformed pre-B cells by suppressing RAG1/2 expression and activity. Blood 126, 1324-35
26153519   Curated Info

6

Niedan S, et al. (2014) Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma. Oncogene 33, 3927-38
23995784   Curated Info

7

Rikova K, Hall B (2013) CST Curation Set: 20734, 21161, 30112, 30153, 30154; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

8

Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

9

Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

10

Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

11

Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

12

Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

13

Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

14

Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

15

Masui K, et al. (2013) mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metab 18, 726-39
24140020   Curated Info

16

Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

17

Rikova K (2013) CST Curation Set: 18529; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST], LXRXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXXS*/T*) (110B7E) Rabbit mAb Cat#: 9614 Phospho-AMPK Substrate Motif [LXRXX(pS/pT) MultiMab(TM) Rabbit mAb mix Cat#: 5759
Curated Info

18

Rikova K (2012) CST Curation Set: 16151; Year: 2012; Biosample/Treatment: cell line, H1703/gleevec; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST], LXRXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXXS*/T*) (110B7E) Rabbit mAb Cat#: 9614 Phospho-AMPK Substrate Motif [LXRXX(pS/pT) MultiMab(TM) Rabbit mAb mix Cat#: 5759
Curated Info

19

Villagrasa P, et al. (2012) Akt2 interacts with Snail1 in the E-cadherin promoter. Oncogene 31, 4022-33
22158034   Curated Info

20

Verano-Braga T, et al. (2012) Time-resolved quantitative phosphoproteomics: new insights into Angiotensin-(1-7) signaling networks in human endothelial cells. J Proteome Res 11, 3370-81
22497526   Curated Info

21

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

22

Rikova K (2012) CST Curation Set: 14275; Year: 2012; Biosample/Treatment: cell line, Tumor pilot study 2mg/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

23

Mulhern D (2011) CST Curation Set: 12841; Year: 2011; Biosample/Treatment: cell line, HEK 293/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

24

Fafalios A, et al. (2011) A hepatocyte growth factor receptor (Met)-insulin receptor hybrid governs hepatic glucose metabolism. Nat Med 17, 1577-84
22081023   Curated Info

25

Moritz A (2011) CST Curation Set: 12513; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

26

Moritz A (2011) CST Curation Set: 11934; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

27

Moritz A (2011) CST Curation Set: 11935; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

28

Moritz A (2011) CST Curation Set: 11936; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

29

Moritz A (2011) CST Curation Set: 11937; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

30

Moritz A (2011) CST Curation Set: 11938; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

31

Moritz A (2011) CST Curation Set: 11939; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

32

Moritz A (2011) CST Curation Set: 11940; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

33

Moritz A (2011) CST Curation Set: 11944; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

34

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

35

Roy SK, et al. (2011) Resveratrol inhibits growth of orthotopic pancreatic tumors through activation of FOXO transcription factors. PLoS One 6, e25166
21980390   Curated Info

36

Possemato A (2010) CST Curation Set: 10791; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

37

Qiang L, Banks AS, Accili D (2010) Uncoupling of acetylation from phosphorylation regulates FoxO1 function independent of its subcellular localization. J Biol Chem 285, 27396-401
20519497   Curated Info

38

Banerjee A, et al. (2010) Hepatitis C virus differentially modulates activation of forkhead transcription factors and insulin-induced metabolic gene expression. J Virol 84, 5936-46
20357092   Curated Info

39

Qiao M, et al. (2010) Mst1 is an interacting protein that mediates PHLPPs' induced apoptosis. Mol Cell 38, 512-23
20513427   Curated Info

40

Possemato A (2010) CST Curation Set: 9629; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

41

Possemato A (2010) CST Curation Set: 9628; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

42

Possemato A (2010) CST Curation Set: 9619; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

43

Kim S, Kim Y, Lee J, Chung J (2010) Regulation of FOXO1 by TAK1-Nemo-like kinase pathway. J Biol Chem 285, 8122-9
20061393   Curated Info

44

Singh A, et al. (2010) Protein phosphatase 2A reactivates FOXO3a through a dynamic interplay with 14-3-3 and AKT. Mol Biol Cell 21, 1140-52
20110348   Curated Info

45

Yoshimochi K, Daitoku H, Fukamizu A (2010) PCAF represses transactivation function of FOXO1 in an acetyltransferase-independent manner. J Recept Signal Transduct Res 30, 43-9
20041807   Curated Info

46

Chresta CM, et al. (2010) AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 70, 288-98
20028854   Curated Info

47

Zhong D, et al. (2009) The Glycolytic Inhibitor 2-Deoxyglucose Activates Multiple Prosurvival Pathways through IGF1R. J Biol Chem 284, 23225-33
19574224   Curated Info

48

Guo A (2009) CST Curation Set: 6064; Year: 2010; Biosample/Treatment: cell line, 293/Torin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

49

Chabot C, et al. (2009) New role for the protein tyrosine phosphatase DEP-1 in Akt activation and endothelial cell survival. Mol Cell Biol 29, 241-53
18936167   Curated Info

50

Koomoa DL, et al. (2008) Ornithine decarboxylase inhibition by alpha-difluoromethylornithine activates opposing signaling pathways via phosphorylation of both Akt/protein kinase B and p27Kip1 in neuroblastoma. Cancer Res 68, 9825-31
19047162   Curated Info

51

Yamagata K, et al. (2008) Arginine methylation of FOXO transcription factors inhibits their phosphorylation by Akt. Mol Cell 32, 221-31
18951090   Curated Info

52

Brent MM, Anand R, Marmorstein R (2008) Structural basis for DNA recognition by FoxO1 and its regulation by posttranslational modification. Structure 16, 1407-16
18786403   Curated Info

53

Valenti L, et al. (2008) Increased expression and activity of the transcription factor FOXO1 in nonalcoholic steatohepatitis. Diabetes 57, 1355-62
18316359   Curated Info

54

Crellin NK, Garcia RV, Levings MK (2007) Altered activation of AKT is required for the suppressive function of human CD4+CD25+ T regulatory cells. Blood 109, 2014-22
17062729   Curated Info

55

Crean JK, et al. (2006) Connective tissue growth factor/CCN2 stimulates actin disassembly through Akt/protein kinase B-mediated phosphorylation and cytoplasmic translocation of p27(Kip-1). FASEB J 20, 1712-4
16790529   Curated Info

56

Armoni M, et al. (2006) FOXO1 represses peroxisome proliferator-activated receptor-gamma1 and -gamma2 gene promoters in primary adipocytes. A novel paradigm to increase insulin sensitivity. J Biol Chem 281, 19881-91
16670091   Curated Info

57

Fosbrink M, et al. (2006) C5b-9-induced endothelial cell proliferation and migration are dependent on Akt inactivation of forkhead transcription factor FOXO1. J Biol Chem 281, 19009-18
16670089   Curated Info

58

Tomita Y, et al. (2006) Prognostic significance of activated AKT expression in soft-tissue sarcoma. Clin Cancer Res 12, 3070-7
16707604   Curated Info

59

Mungamuri SK, Yang X, Thor AD, Somasundaram K (2006) Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res 66, 4715-24
16651424   Curated Info

60

Matsuzaki H, et al. (2005) Acetylation of Foxo1 alters its DNA-binding ability and sensitivity to phosphorylation. Proc Natl Acad Sci U S A 102, 11278-83
16076959   Curated Info

61

Gan L, et al. (2005) Nuclear/cytoplasmic shuttling of the transcription factor FoxO1 is regulated by neurotrophic factors. J Neurochem 93, 1209-19
15934941   Curated Info

62

Di Maira G, et al. (2005) Protein kinase CK2 phosphorylates and upregulates Akt/PKB. Cell Death Differ 12, 668-77
15818404   Curated Info

63

Sabnis GJ, Jelovac D, Long B, Brodie A (2005) The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. Cancer Res 65, 3903-10
15867390   Curated Info

64

Smith WW, et al. (2005) Phosphorylation of p66Shc and forkhead proteins mediates Abeta toxicity. J Cell Biol 169, 331-9
15837797   Curated Info

65

Yau CY, Wheeler JJ, Sutton KL, Hedley DW (2005) Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts. Cancer Res 65, 1497-504
15735038   Curated Info

66

Huang H, et al. (2005) Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc Natl Acad Sci U S A 102, 1649-54
15668399   Curated Info

67

Horn S, et al. (2004) Restoration of SHIP activity in a human leukemia cell line downregulates constitutively activated phosphatidylinositol 3-kinase/Akt/GSK-3beta signaling and leads to an increased transit time through the G1 phase of the cell cycle. Leukemia 18, 1839-49
15457186   Curated Info

68

Zhao X, et al. (2004) Multiple elements regulate nuclear/cytoplasmic shuttling of FOXO1: characterization of phosphorylation- and 14-3-3-dependent and -independent mechanisms. Biochem J 378, 839-49
14664696   Curated Info

69

Barnes CJ, et al. (2003) Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa). Mol Cancer Ther 2, 345-51
12700278   Curated Info

70

Astoul E, et al. (2003) Approaches to define antigen receptor-induced serine kinase signal transduction pathways. J Biol Chem 278, 9267-75
12515807   Curated Info

71

Zhang X, et al. (2002) Phosphorylation of serine 256 suppresses transactivation by FKHR (FOXO1) by multiple mechanisms. Direct and indirect effects on nuclear/cytoplasmic shuttling and DNA binding. J Biol Chem 277, 45276-84
12228231   Curated Info

72

Rena G, et al. (2002) Two novel phosphorylation sites on FKHR that are critical for its nuclear exclusion. EMBO J 21, 2263-71
11980723   Curated Info

73

Woods YL, et al. (2001) The kinase DYRK1A phosphorylates the transcription factor FKHR at Ser329 in vitro, a novel in vivo phosphorylation site. Biochem J 355, 597-607
11311120   Curated Info

74

Rena G, et al. (2001) Roles of the forkhead in rhabdomyosarcoma (FKHR) phosphorylation sites in regulating 14-3-3 binding, transactivation and nuclear targetting. Biochem J 354, 605-12
11237865   Curated Info

75

Jackson JG, et al. (2000) Phosphorylation and nuclear exclusion of the forkhead transcription factor FKHR after epidermal growth factor treatment in human breast cancer cells. Oncogene 19, 4574-81
11030146   Curated Info

76

Guo S, et al. (1999) Phosphorylation of serine 256 by protein kinase B disrupts transactivation by FKHR and mediates effects of insulin on insulin-like growth factor-binding protein-1 promoter activity through a conserved insulin response sequence. J Biol Chem 274, 17184-92
10358076   Curated Info

77

Rena G, et al. (1999) Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B. J Biol Chem 274, 17179-83
10358075   Curated Info